Date: {{$ActivityAssignDate}}

Dear Dr. {{ $doctorName }},

Subject: A Survey of Healthcare Practitioners in India on the Epidemiology and Treatment Options for Atopic Dermatitis

Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. It is commonly associated with other atopic disorders such as asthma and allergic rhinitis. The pathogenesis of AD involves a complex interplay between genetic predisposition, environmental factors, skin barrier dysfunction, and immune dysregulation. Recent studies have highlighted the role of Th2-mediated immune responses and the importance of cytokines such as IL-4, IL-13, and IL-31 in the development and exacerbation of AD. Advances in understanding the molecular mechanisms underlying AD have led to the development of targeted therapies, including biologics, which have shown significant efficacy in reducing symptoms and improving the quality of life for patients.

Management of atopic dermatitis typically involves a combination of skincare routines, pharmacological treatments, and lifestyle modifications. First-line treatments include the use of emollients to maintain skin hydration and topical corticosteroids to reduce inflammation. For moderate to severe cases, systemic immunomodulator treatments such as cyclosporine, methotrexate, and newer biologics are recommended. Phototherapy is another option for patients who do not respond adequately to topical treatments. Recent guidelines emphasize the importance of a personalized approach to treatment, considering the severity of the disease, patient preferences, and potential side effects. Ongoing research continues to explore novel therapeutic targets and strategies to improve the management of this burdensome condition.

This survey has been undertaken to understand epidemiology and various treatment options for management of atopic dermatitis by healthcare practitioners (HCP) in India.

As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.

We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.